MedTrace Logo

A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice

NCT05637112 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 551

Last updated 2026-02-24

No results posted yet for this study

Summary

Anifrolumab Study of Treatment Effectiveness in the Real World (ASTER) study will collect real world data to obtain a good understanding of the (sustained) clinical effect and patient quality of life outcomes among diagnosed SLE patients who initiate anifrolumab treatment. ASTER will generate critical real-world evidence on the benefits of adding anifrolumab to standard of care treatment for SLE in routine clinical practice, to inform physicians, payers and patients.

Conditions

Interventions

OTHER

None (Observational study)

Not Applicable since Observational Study

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-27
Primary Completion
2030-12-30
Completion
2030-12-30

Countries

  • Austria
  • Belgium
  • Canada
  • France
  • Germany
  • Israel
  • Italy
  • Sweden
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05637112 on ClinicalTrials.gov